Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17591351 | 0.84 | ATM (0.54) | SMN1; SMN2TRPV1NPC1RAB9AMAPT | |
| SCHEMBL15498258 | 0.81 | POLB (0.45) | SMN1; SMN2GFERTRPV1NPC1RAB9A | |
| SCHEMBL20037624 | 0.80 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9AMAPTMEN1 | |
| SCHEMBL15221722 | 0.79 | TDP1 (0.50) | SMN1; SMN2MAPTMEN1KMT2AKDM4E | |
| SCHEMBL23213553 | 0.79 | P4HTM (0.45) | SMN1; SMN2TRPV1NPC1RAB9AMAPT | |
| SCHEMBL2611229 | 0.78 | L3MBTL1 (0.60) | SMN1; SMN2NPC1RAB9AMAPTMEN1 | |
| SCHEMBL12091529 | 0.76 | TRPV1 (0.43) | SMN1; SMN2TRPV1NPC1RAB9AMAPT | |
| SCHEMBL20037623 | 0.76 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9AMAPTMEN1 | |
| SCHEMBL18291583 | 0.76 | SMN1; SMN2 (0.48) | SMN1; SMN2TRPV1NPC1RAB9AMAPT | |
| SCHEMBL31363779 | 0.74 | NAMPT (0.51) | CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | SMN1; SMN2 1690/4885GFER 4611/4885TRPV1 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.